|Bid||129.41 x 100|
|Ask||129.66 x 100|
|Day's Range||128.35 - 129.75|
|52 Week Range||123.73 - 192.15|
|PE Ratio (TTM)||9.17|
|Forward Dividend & Yield||1.05 (0.81%)|
|1y Target Est||N/A|
A federal judge has dismissed a lawsuit by the U.S. Federal Trade Commission accusing a unit of Shire Plc of violating antitrust laws by abusing government processes to fend off generic competition to its antibiotic Vancocin HCl. U.S. District Judge Richard Andrews in Wilmington, Delaware on Tuesday ruled the FTC had not met a prerequisite for bringing a lawsuit seeking an injunction in the first place by showing that Shire ViroPharma Inc was about to violate a law. The FTC and Dublin-based Shire did not immediately respond to requests for comment on Wednesday.
Moody's Investors Service ("Moody's") affirmed the Baa3 issuer rating of Shire plc and the Baa3 senior unsecured ratings of rated subsidiaries including Shire Acquisitions Investments Ireland ...
Based on readouts from this study, the company plans to evaluate the efficacy and safety of once-a-week semaglutide therapy in NASH indications in its Phase 3 trial. According to a Diabetes Care report, ~80% of NASH patients suffer from obesity.
Shares of biopharmaceutical company Caladrius Biosciences Inc (NASDAQ:CLBS) are soaring nearly 25% to $6.35 in pre-market trading Tuesday. All of this appears to be a result of CLBS's announcement this morning that it has entered into a definitive agreement with Shire (NASDAQ:SHPG) to acquire a late stage CD34+ cell therapy program for the treatment of chronic myocardial ischemia targeting refractory angina. Valuation-wise, it's hard to say whether CMC is getting a good price on this asset. Under the terms of the agreement, Caladrius acquired the exclusive worldwide rights to the data set and regulatory filings for the CD34+ cell therapy program for the treatment of refractory angina. In exchange, Shire will receive undisclosed up-front consideration, milestones and a royalty on product sales.
Shire plc (LSE:SHP) delivered a less impressive 11.76% ROE over the past year, compared to the 16.09% return generated by its industry. An investor may attribute an inferior ROE toRead More...
The Soros Fund Management reportedly sold its entire holdings of Acadia Pharmaceuticals and Shire plc in the fourth quarter of 2017.
Shire plc’s (NASDAQ:SHPG) most recent return on equity was a substandard 4.97% relative to its industry performance of 16.36% over the past year. SHPG’s results could indicate a relatively inefficientRead More...
Shire (SHPG) reported better-than-expected fourth-quarter earnings and also registered strong growth in immunology franchise and newly launched products.
Shire, which is splitting its rare disease and hyperactivity drugs into separate units, said 2018 sales would grow in mid-single figures and profits would rise at an even slower pace. The London-listed pharmaceuticals firm reported full-year revenue on Wednesday of $15.16 billion (10.94 billion pounds), up 33 percent, and non-GAAP diluted earnings per American Depositary Share of $15.15, up 16 percent and towards the top of its guidance. Chief Executive Flemming Ornskov said 2017 growth was boosted by a strong performance from its immunology medicines.
Shire, which is splitting its rare disease and hyperactivity drugs into separate units, said 2018 sales would grow in mid-single figures and profits would rise at an even slower pace. The London-listed pharmaceuticals firm reported full-year revenue on Wednesday of $15.16 billion, up 33 percent, and non-GAAP diluted earnings per American Depositary Share of $15.15, up 16 percent and towards the top of its guidance. Chief Executive Flemming Ornskov said 2017 growth was boosted by a strong performance from its immunology medicines.
On a per-share basis, the Dublin-based company said it had profit of $10.22. Earnings, adjusted for one-time gains and costs, were $3.98 per share. The results surpassed Wall Street expectations. The average ...
Shire, the pharma firm splitting its rare disease and hyperactivity drugs into two units, said sales would grow in the mid-single digits and profits by a lower percentage than the top line this year after ...
Shire plc (LSE:SHP) is trading with a trailing P/E of 26.1x, which is lower than the industry average of 26.8x. While this makes SHP appear like a great stock toRead More...
Simon Property Group Inc (SPG), Ford Motor Co (F), Shire PLC (SHPG), and Public Storage (PSA) have declined to their respective three-year lows.
Shire (SHPG) receives an FDA approval for transferring the product manufacturing technology of its hereditary angioedema drug, Cinryze, to its manufacturing site in Vienna, Austria.
In 3Q17, Bioverativ’s (BIVV) drug Alprolix generated revenue of $88.5 million, which reflected a rise of ~4% on a year-over-year (or YoY) basis. In 3Q17, Alprolix contributed ~32.2% of Bioverativ’s net product sales. Alprolix reported revenue of $264.2 million in the first nine months of 2017 (which ended in September 2017) compared to its revenue of $240.5 million in the first nine months of 2016.